Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prometheus Biosciences Inc (NQ: RXDX )

109.68 -0.63 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 277,933
Open 110.31
Bid (Size) 105.10 (1)
Ask (Size) 114.32 (1)
Prev. Close 110.31
Today's Range 109.18 - 111.90
52wk Range 21.50 - 129.60
Shares Outstanding 41,700,063
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Prometheus Biosciences
Via Globe NewsWire

Performance

YTD
+2.89%
+2.89%
1 Month
-7.66%
-7.66%
3 Month
+0.88%
+0.88%
6 Month
+117.10%
+117.10%
1 Year
+187.05%
+187.05%

More News

Read More
Analyst Expectations for Prometheus Biosciences's Future
Via Benzinga
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
From Prometheus Biosciences
Via Globe NewsWire
Analyst Expectations for Prometheus Biosciences's Future
Via Benzinga
Looking Into Prometheus Biosciences's Return On Capital Employed
Via Benzinga
Where Prometheus Biosciences Stands With Analysts
Via Benzinga
Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)
From Prometheus Biosciences
Via Globe NewsWire
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
From Prometheus Biosciences
Via Globe NewsWire
How Is The Market Feeling About Prometheus Biosciences?
Via Benzinga
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Prometheus Biosciences
Via Globe NewsWire
Bulls In A Bear Market: These 10 Stocks Clocked Gains In Excess Of 100% In 2022
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
Via Benzinga
Why Prometheus Biosciences Stock Is Falling
Via Benzinga
Is Prometheus Biosciences a Good Stock to Buy Right Now?
Via The Motley Fool
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
From Prometheus Biosciences
Via Globe NewsWire
Why Prometheus Biosciences Stock Is Rocketing Higher Today
Via Benzinga
Analyzing Prometheus Biosciences's Short Interest
Via Benzinga
Why Shares of Prometheus Biosciences Are Soaring This Week
Via The Motley Fool
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Lowe's To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
Via Benzinga
Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
From Prometheus Biosciences
Via Globe NewsWire
Dow Edges Higher; Prometheus Biosciences Shares Jump
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.